TALOPH(SH:600222) Shang Hai Zheng Quan Bao·2025-06-12 19:31Summary of Key Points Core Viewpoint - The company has provided a guarantee of 20 million RMB for its subsidiary, Beijing New Leading Pharmaceutical Technology Development Co., Ltd., to support its financing needs, which is part of a broader strategy to enhance operational efficiency and financial stability [2][11]. Group 1: Guarantee Details - The guarantee amount for the subsidiary is 20 million RMB, with a total guarantee balance of 108.17 million RMB as of the announcement date [2][14]. - The guarantee is provided without any counter-guarantee and there are no overdue guarantees [3][14]. - The guarantee is part of a maximum guarantee limit of 430 million RMB approved for the fiscal year 2025 [4][14]. Group 2: Subsidiary Information - Beijing New Leading has a registered capital of 91.55 million RMB and is primarily engaged in medical research and technology services [6][8]. - The company holds an 87.38% stake in the subsidiary, indicating significant control over its operations [8][12]. Group 3: Guarantee Agreement - The guarantee agreement with Beijing Bank Zhongguancun Branch includes a maximum principal amount of 20 million RMB and covers all debts, including principal, interest, penalties, and other related costs [9][11]. - The guarantee period extends for three years from the maturity of the secured debt [10]. Group 4: Board's Opinion - The board of directors believes that the guarantee is necessary for the subsidiary's operational growth and aligns with the company's strategic goals, ensuring that the subsidiary can meet its financial obligations [13].